Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:459-464
doi: 10.1161/01.CIR.0000153850.53419.50
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laflamme, K.
Right arrow Articles by Germain, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laflamme, K.
Right arrow Articles by Germain, L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Contractile function
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow Receptor pharmacology

(Circulation. 2005;111:459-464.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Tissue-Engineered Human Vascular Media With a Functional Endothelin System

Karina Laflamme, MSc; Charles J. Roberge, PhD; Julie Labonté, MSc; Stéphanie Pouliot, DEC; Pédro D’Orléans-Juste, PhD; François A. Auger, MD, FRCP; Lucie Germain, PhD

From the Laboratoire d’Organogénèse Expérimentale/LOEX, Hôpital Saint-Sacrement du CHA, and Department of Surgery, Laval University, Québec, PQ, Canada (K.L., C.J.R., F.A.A., L.G., S.P.), and Institute of Pharmacology, Medical School, Sherbrooke University, Sherbrooke, PQ, Canada (J.L., P.D.J.).

Correspondence to Dr Lucie Germain, Laboratoire d’Organogénèse Expérimentale, Hôpital du Saint-Sacrement du CHA, 1050 Chemin Ste-Foy, Québec, Qc, Canada G1S-4L8. E-mail lucie.germain{at}chg.ulaval.ca

Received September 16, 2004; accepted October 20, 2004.

Background— Cardiovascular diseases remain a major cause of death and disability in the Western world. Among the various approaches adopted to counteract the morbidity associated with these diseases, surgical procedures and cardiac and vascular xenotransplantations or allotransplantations are routinely performed. The suitable vascular graft would be as close as possible to the native and healthy vessel composed exclusively of human components provided by the patient and would adapt to the donor’s hemodynamics. We have developed such a tissue-engineered human blood vessel reconstructed with human cells. Because endothelin is the most potent vasopressor known to date, we were interested in investigating the functionality of the endothelinergic system in our reconstructed human blood vessel.

Methods and Results— Vasoconstriction studies were performed with nonselective and selective agonists and antagonists to demonstrate that ETA receptors were present and functional in tissue-engineered human vascular media constructed with the self-assembly method. Reverse-transcriptase polymerase chain reaction studies demonstrated that mRNA of the ETA but not the ETB receptor was present in these human tissue–engineered blood vessels. Furthermore, we demonstrated that the endothelin-converting enzyme, the main enzyme responsible for the formation of the biologically active endothelin peptides, was present and functional in these same bioengineered vascular media.

Conclusions— Our results suggest that the media component of our tissue-engineered blood vessel has the potential of controlling vascular resistance via the presence of functional endothelin ETA receptors and endothelin-converting enzyme.


Key Words: endothelin • muscle contraction • myocytes, smooth muscle




This article has been cited by other articles:


Home page
Cancer Res.Home page
P.-L. Tremblay, J. Huot, and F. A. Auger
Mechanisms by which E-Selectin Regulates Diapedesis of Colon Cancer Cells under Flow Conditions
Cancer Res., July 1, 2008; 68(13): 5167 - 5176.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. J. Pagano and D. D. Gutterman
The adventitia: The outs and ins of vascular disease
Cardiovasc Res, September 1, 2007; 75(4): 636 - 639.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. A. Auger, P. D'Orleans-Juste, and L. Germain
Adventitia contribution to vascular contraction: Hints provided by tissue-engineered substitutes
Cardiovasc Res, September 1, 2007; 75(4): 669 - 678.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. Laflamme, C. J. Roberge, G. Grenier, M. Remy-Zolghadri, S. Pouliot, K. Baker, R. Labbe, P. D'Orleans-Juste, F. A. Auger, and L. Germain
Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel
FASEB J, June 1, 2006; 20(8): 1245 - 1247.
[Abstract] [Full Text] [PDF]